Changes in Nasal Resistance and Nasal Geometry Using Pressure and Acoustic Rhinometry in a Feline Model of Nasal Congestion

McLeod, Robbie L.; Mingo, Garfield G.; Herczku, Christine; Corboz, Michel R.; Ramos, Sonia I.; DeGennaro-Culver, Frances; Pedersen, Ole F.; Hey, John A.

doi:10.2500/105065899781367573

Cited by 21 publications

(24 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 In the present study, PPA (1.0 mg/kg i.v.) attenuated the congestive actions of aerosolized compound 48/80 (Table I).…”

Section: Effect Of Histamine H/h3 Receptor Blockade On Nasalmentioning

confidence: 99%

Combined Histamine H₁ and H₃ Receptor Blockade Produces Nasal Decongestion in an Experimental Model of Nasal Congestion

McLeod¹,

Mingo²,

Herczku³

et al. 1999

American Journal of Rhinology

Self Cite

View full text Add to dashboard Cite

We studied the pharmacological actions of combined histamine H1/H3 receptor blockade on the increase in nasal airway resistance (NAR) and decrease in nasal cavity volume produced by nasal exposure to compound 48/80, a mast cell degranulator. In the anesthetized cat compound 48/80 (1%) produced a maximum increase in NAR of 9.1 +/- 0.7 cmH20.L/minute. The increase in NAR in animals pretreated with a combination of the H1 antagonist, chlorpheniramine (CTM; 0.8 mg/kg i.v.) and increasing doses of the H3 antagonist, thioperamide (THIO; 1.0, 3.0, and 10.0 mg/kg i.v.) were 6.1 +/- 2.1, 4.2 +/- 1.0 and 2.2 +/- 0.7 cmH20.L/minute, respectively. A second H3 antagonist, clobenpropit (CLOB; 0.03, 0.3, and 1.0 mg/kg i.v.) combined with CTM (0.8 mg/kg i.v.) also inhibited the nasal effects of compound 48/80. When the nonsedating H1 antihistamine, loratadine (3.0 mg/kg i.v.), was substituted for CTM, it also reduced nasal congestion when given in combination with THIO (10 mg/kg i.v.). In contrast, treatment with CTM (1.0 mg/kg i.v.) and the H2 antagonist, ranitidine (RAN; 1.0 mg/kg i.v.) were without activity. Loratadine, CTM, CLOB, RAN, or THIO administered alone were inactive. The alpha-adrenergic agonist, phenylpropanolamine (PPA; 1.0 mg/kg i.v.) demonstrated decongestant effects, but in contrast to H1/H3 blockade, PPA produced a significant hypertensive effect. Using acoustic rhinometry (AcR) we found that combined i.v. CTM (1.0 mg/kg) and THIO (10 mg/kg) and combined oral CTM (10 mg/kg) and THIO (30 mg/kg) blocked the decrease in nasal cavity volume produced by intranasal compound 48/80 (1%, 50 microL). We conclude that combined H1/H3 histamine receptor blockade enhances the efficacy of an H1 antagonist by conferring decongestant activity to the H1 antihistamine. We propose that the decongestant activity of combined H1/H3 blockade may provide a novel approach for the treatment of allergic nasal congestion without the hypertensive liability of current therapies.

show abstract

“…19 In the present study, PPA (1.0 mg/kg i.v.) attenuated the congestive actions of aerosolized compound 48/80 (Table I).…”

Section: Effect Of Histamine H/h3 Receptor Blockade On Nasalmentioning

confidence: 99%

Combined Histamine H₁ and H₃ Receptor Blockade Produces Nasal Decongestion in an Experimental Model of Nasal Congestion

McLeod¹,

Mingo²,

Herczku³

et al. 1999

American Journal of Rhinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…were administered in order to maintain an appropriate depth of anesthesia. As previously described, an acoustic rhinometer (Nadar, Aarhus, Denmark) was used to determine nasal cavity volumes from a distance of 0-3 cm into the nasal cavity [10,17,18] . The equipment consisted of a spark sound generator, a wave tube, a microphone with an amplifier and a computer for data acquisition.…”

Section: Acoustic Rhinometry and Blood Pressure Measurementsmentioning

confidence: 99%

Alpha-2c-Adrenergic Receptors Contribute to Basal Nasal Patency in the Anesthetized Cat

Mingo¹,

Corboz²,

Salisbury³

et al. 2010

Pharmacology

Self Cite

View full text Add to dashboard Cite

Background: Nasal congestion is the most troublesome symptom associated with a variety of upper airway diseases, including allergic rhinitis and the common cold. A better understanding of the mechanisms that regulate nasal cavity caliber may engender the development of novel treatment strategies. It is well accepted that α-adrenergic (both α₁ and α₂) mechanisms play a fundamental role in the control and maintenance of basal nasal patency. JP-1302 is a selective α_2c-subtype antagonist that has been recently described in the scientific literature. Thus, we sought to examine the potential effects of this new pharmacological tool on basal nasal patency. Methods: Using acoustic rhinometry, we studied the activity of the selective α_2c-antagonist JP-1302 on nasal cavity volumes in an anesthetized cat. Cumulative concentrations of JP-1302 were applied directly into the right nasal cavity. Changes in the nasal cavity geometry of the drug-treated naris relative to the untreated left nasal cavity were determined. In separate studies, the nonselective α₂-antagonist yohimbine and the nonselective α₁-antagonist prazosin were run as comparators. Systolic blood pressure was measured at the hind leg, using an ultrasonic Doppler flow detector. Results: JP-1302 (0.03, 0.1, 0.3 and 1.0%) administered by the intranasal route decreased nasal cavity volumes from baseline values by 17, 25, 40 and 40%, respectively. Yohimbine (0.03, 0.1, 0.3 and 1.0%) decreased volumes by 19, 36, 46 and 53%, and topical administration of the nonselective α₁-antagonist prazosin (0.001, 0.003, 0.01, 0.03 and 0.1%) decreased volumes by 6, 47, 56, 64 and 71%, respectively. JP-1302, yohimbine and prazosin, at the dose level tested, did not alter the blood pressure. Conclusions: The present set of experiments indicates that both α₁- and α₂-adrenergic receptors are involved in the maintenance of basal nasal patency in the cat. Moreover, α_2c-receptors may play a significant role in the sympathetic control of upper airway function.

show abstract

“…Recent studies (4,13,14,(16)(17)(18) have used dogs and cats for drug evaluation. Terheyden et al (26) summarize several attempts to validate how precisely AR measures the nasal cavity in humans, including validation of AR by magnetic resonance (MR) imaging (2,8) and by a fluid-displacement method (FDM) (7).…”

mentioning

confidence: 99%

Acoustic rhinometry in dog and cat compared with a fluid-displacement method and magnetic resonance imaging

Straszek¹,

Taagehøj²,

Graff³

et al. 2003

Journal of Applied Physiology

View full text Add to dashboard Cite

. Acoustic rhinometry in dog and cat compared with a fluid-displacement method and magnetic resonance imaging. J Appl Physiol 95: 635-642, 2003. First published April 18, 2003 10.1152/japplphysiol.01105. 2002.-An increasing number of studies have used acoustic rhinometry (AR) for study of pharmacological interventions on nasal cavity dimensions in dogs and cats, but there have been no attempts to validate AR in these species. This is done in the present study. We compared area-distance relationships of nasal cavities from five decapitated dogs (3.5-41 kg) and cats (3.8-6 kg). AR was compared with magnetic resonance (MR) imaging and a fluid-displacement method (FDM) using perfluorocarbon. AR measured 88% (98-79%) (mean and 95% confidence interval) of nasal cavity volume in dogs determined by FDM and 71% (83-59%) in cats. AR markedly underestimated nasal cavity dimensions when minimum areas were below 0.1 cm 2 in dogs and 0.05 cm 2 in cats. AR underestimation increased with the severity of the constriction and with distance. Cross-sectional areas in the deeper parts of the cavity measured 76% (99-54%) of FDM in dogs and 52% (66-39%) in cats. AR agreed well with MR, especially in the deeper part of the cavity. MR images showed that the nasal cavities had a very complex structure not expected to be reproduced by AR. MR could not be considered a "gold standard" because definition of the cross-sectional area of the lumen depended critically on subjective choices. FDM produced repeatable measurements and possibly offers the most adequate reference in future evaluation of AR. AR underestimated what we believed were the most correct cross-sectional areas determined by FDM, especially in the deeper part of the dog and cat nasal cavities. Despite these difficulties, AR has been shown to be useful to describe qualitative changes in cross-sectional area. nasal airway volume; nasal pharmacology; laboratory animals; rhinology

show abstract

Changes in Nasal Resistance and Nasal Geometry Using Pressure and Acoustic Rhinometry in a Feline Model of Nasal Congestion

Cited by 21 publications

References 24 publications

Combined Histamine H₁ and H₃ Receptor Blockade Produces Nasal Decongestion in an Experimental Model of Nasal Congestion

Combined Histamine H₁ and H₃ Receptor Blockade Produces Nasal Decongestion in an Experimental Model of Nasal Congestion

Alpha-2c-Adrenergic Receptors Contribute to Basal Nasal Patency in the Anesthetized Cat

Acoustic rhinometry in dog and cat compared with a fluid-displacement method and magnetic resonance imaging

Contact Info

Product

Resources

About

Changes in Nasal Resistance and Nasal Geometry Using Pressure and Acoustic Rhinometry in a Feline Model of Nasal Congestion

Cited by 21 publications

References 24 publications

Combined Histamine H1 and H3 Receptor Blockade Produces Nasal Decongestion in an Experimental Model of Nasal Congestion

Combined Histamine H1 and H3 Receptor Blockade Produces Nasal Decongestion in an Experimental Model of Nasal Congestion

Alpha-2c-Adrenergic Receptors Contribute to Basal Nasal Patency in the Anesthetized Cat

Acoustic rhinometry in dog and cat compared with a fluid-displacement method and magnetic resonance imaging

Contact Info

Product

Resources

About

Combined Histamine H₁ and H₃ Receptor Blockade Produces Nasal Decongestion in an Experimental Model of Nasal Congestion

Combined Histamine H₁ and H₃ Receptor Blockade Produces Nasal Decongestion in an Experimental Model of Nasal Congestion